跳至主要内容
临床试验/EUCTR2014-001259-22-Outside-EU/EEA
EUCTR2014-001259-22-Outside-EU/EEA进行中(未招募)1 期

open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year old

Boehringer Ingelheim (Canada) Ltd/Ltée0 个研究点目标入组 12 人开始时间: 2016年8月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Neonates and infants with aged < 12 months at Visit 1
  • - Objective diagnosis of VTE
  • - End of planned treatment course with anticoagulant therapy as per standard of care at the investigator site.
  • - Written informed consent provided by the patient's parent(s) (or legal guardian) according to local regulations at Visit 1.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 8
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Weight less than 3 kg at Visit 1
  • - Conditions associated with an increased risk of bleeding
  • - renal dysfunction
  • - hepatic disease
  • - Anemia or thrombocytopenia at screening

研究者

发起方
Boehringer Ingelheim (Canada) Ltd/Ltée

相似试验

进行中(未招募)
不适用
Tolerability , PK/PD and safety of dabigatran etexilate oral liquid formulation in children < 1 year of agevenous thrombotic eventMedDRA version: 17.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866
EUCTR2014-001259-22-ATBoehringer Ingelheim RCV GmbH & Co KG12
进行中(未招募)
1 期
Tolerability , PK/PD and safety of dabigatran etexilate oral liquid formulation in children < 1 year of agevenous thrombotic eventMedDRA version: 18.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866
EUCTR2014-001259-22-FRBoehringer Ingelheim France12
进行中(未招募)
不适用
Tolerability , PK/PD and safety of dabigatran etexilate oral liquid formulation in children < 1 year of agevenous thrombotic eventMedDRA version: 17.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866
EUCTR2014-001259-22-ITBoehringer Ingelheim Italia S.p.A.12
进行中(未招募)
1 期
A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years.Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc.MedDRA version: 20.1Level: LLTClassification code 10028603Term: Myocardial perfusion scanSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10065141Term: Vascular diagnostic procedureSystem Organ Class: 100000004848
EUCTR2019-002615-25-GBGE Healthcare Ltd.54
进行中(未招募)
1 期
A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years.Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc.MedDRA version: 20.1Level: LLTClassification code 10028603Term: Myocardial perfusion scanSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10065141Term: Vascular diagnostic procedureSystem Organ Class: 100000004848
EUCTR2019-002615-25-GRGE Healthcare Ltd.54